Pfizer's (PFE -0.6%) breast cancer drug Aromasin worsened bone loss in a trial of at-risk...

|About: Pfizer Inc. (PFE)|By:, SA News Editor

Pfizer's (PFE -0.6%) breast cancer drug Aromasin worsened bone loss in a trial of at-risk post-menopausal women, raising the chance of fractures and calling into question whether the pill’s prevention benefits outweigh its risks. The result contradicts earlier studies that suggested the drug may help stimulate bone growth.